Podium to Practice: ESMO® 2025 – GU: RAMPART

Podium to Practice: ESMO® 2025 – GU: RAMPART

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christian Kollmannsberger

Icon Chair Speaker

Speakers

Dr. Sebastien Hotte

Dr. Maria Jiang

Studies / Trials Discussed

LBA93 – First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL

Studies/trials discussed:

LBA93 – First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
Tagged